Results 121 to 130 of about 11,284,409 (311)

Ketogenic diet for infantile epileptic spasms

open access: yesEpilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury   +3 more
wiley   +1 more source

Deuterium-L-DOPA : a novel means to improve treatment of Parkinson's disease

open access: yes, 2012
L-DOPA, the precursor of dopamine, is administered to restore dopamine deficiency in Parkinson´s disease (PD) patients. L-DOPA initially provides a sustained symptomatic relief with superior efficacy as compared to other treatments, while long term ...
Torun Malmlof (18676393)
core  

Somatic cell reprogramming for Parkinson's disease treatment

open access: yesIbrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Serotonin neuromicrobiology: Psychobiotic modulation of the gut–brain axis for mental health

open access: yesIbrain, EarlyView.
An overview of Psychobiotics and Tryptophan metabolism: A serotonin‐kynurenine crosstalk shaping the Gut‐Brain axis. IDO1, Indoleamine 2,3‐dioxygenase 1; 5‐HT3, 5‐hydroxytryptamine type 3; IFN‐γ, Interferon‐gamma; TNF‐α, Tumor necrosis factor‐alpha; IL‐1β, Interleukin‐1 beta; IL‐6, Interleukin 6; Trp, Tryptophan; 5‐HT, 5‐hydroxy‐tryptamine; 5‐HTP, 5 ...
Nidhi Mandloi   +4 more
wiley   +1 more source

L-Dopa and Brain Serotonin System Dysfunction

open access: yes, 2015
L-dopa is used to treat the motor symptoms associated with Parkinson’s disease, a neurodegenerative movement disorder characterized by a loss of dopamine neurons.
Bryan Yamamoto   +3 more
core   +1 more source

Interface Engineering of Boron Nitride–Polymer Composites for High Thermal Conductivity

open access: yesInformation &Functional Materials, EarlyView.
This review comprehensively discusses the impacts of interfacial design and fabrication strategies on boron nitride–polymer composites, and systematically classifies and summarizes recent advances in interfacial engineering based on the interaction modes between boron nitride fillers and polymer matrices.
Zhao Chen   +4 more
wiley   +1 more source

Multi‐omics–driven precision medicine

open access: yesiMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li   +20 more
wiley   +1 more source

Deep brain stimulation (DBS) attentional effects parallel those of l-dopa treatment

open access: yes, 2001
Aim of our study was to investigate the different effects on attentional capacity of deep brain stimulation DBS (STN or GPi) and of l-dopa in PD patients.
Altibrandi, M   +9 more
core  

Hypervision Proton Surgery: The Future Direction of Proton Therapy

open access: yesiNew Medicine, EarlyView.
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley   +1 more source

Home - About - Disclaimer - Privacy